NIKKEI 225
38,370.65 -35.01 (-0.09%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.18 -0.75 (-0.92%) GOLD FUTURES
2,292.80 -10.10 (-0.44%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,265.40 -2,708.35 (-5.31%)
Koninklijke Philips N.V. (PHGN34.SA)
| Previous close | 139.15 |
| Open | 0.00 |
| Bid | 100.49 x N/A |
| Ask | 140.56 x N/A |
| Day's range | 139.15 - 139.15 |
| 52-week range | 89.00 - 148.00 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 126.86B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.42 (3.18%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Globe Newswire
Nicklaus Children’s Health System, Philips to provide innovative patient and staff experience, helping to enhance outcomes for the smallest of patients
Nicklaus Children’s Health System’s Advanced Pediatric Care Pavilion April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic confidence Amsterdam, the Netherlands, and Miami, US – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Nicklaus Children’s Health System, a nationally recognized leader in pediatric care, today announced a 10-year long
- Globe Newswire
Philips delivers first-quarter results in line with 2024 performance improvement plan; Resolves the Respironics personal injury and medical monitoring litigation in the US for USD 1.1 billion
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million)Income from operations EUR -824 million, including above provisionAdjusted EBITA margin of 9.4% of salesFree cash outflow of EUR 336 millionEUR 540 million agreement reached with insurers for Respironics recall-related produ
- GlobeNewswire
Philips Respironics reaches agreement with US government on a consent decree creating a clear path forward
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA. As previously stated: The consent decree primarily focuses on Philips Respironics’ business operations in the US.It provides clarity and a roadmap to demonstrate compliance with regulatory requirements and to restore
